Quantcast

Latest PDE5 inhibitors Stories

2009-06-03 06:00:00

MOUNTAIN VIEW, Calif., June 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Dr. Barbara Troupin, senior director clinical development, will present an overview of the company at the 8th Annual Needham Life Sciences Conference. The VIVUS presentation will take place at the New York Palace Hotel on Thursday, June 11, 2009 at 3:30 p.m. ET. A live webcast and...

2009-05-26 04:22:00

Conference Call to be Held at 9:00 a.m. Eastern Time Today, May 26, 2009 SILVER SPRING, Md., May 26 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, with a recommended dose of 40 mg, as the first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH). ADCIRCA is...

2009-05-23 23:01:39

Robert F. Furchgott, whose research earned him a share of a Nobel Prize and helped lead to the anti-impotency drug Viagra, has died, a daughter said. Susan Furchgott said her father died Tuesday in Seattle, The Ledger in Lakeland, Fla., reported Saturday. He was 92. The elder Furchgott was a pharmacologist who, with Louis J. Ignarro and Ferid Murad, shared the 1998 Nobel for physiology or medicine after proving nitric oxide affected blood pressure and blood flow. Furchgott's discovery that...

2009-05-13 05:30:00

Enrollment in First Pivotal Phase 3 Avanafil Study REVIVE (TA-301) is Complete MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED). VIVUS also announced today that...

2009-05-06 07:00:00

Data Published in May Issue of Journal of Sexual Medicine INDIANAPOLIS, May 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced results from a double-blind, placebo-controlled study which showed that tadalafil 5 mg dose taken once daily was generally well-tolerated, improved erectile function for men with erectile dysfunction (ED) and reported improvement in the sexual quality of life scores for men and their female partners. The 12-week study monitored 342 men...

2009-04-29 13:46:21

The U.S. Food and Drug Administration announced the nationwide recall of Libimax brand sexual supplement due to a safety hazard. The FDA said the Nature & Health Co. of Brea, Calif., initiated the voluntary recall because a FDA lab analysis showed the product contains tadalafil, an active ingredient of an FDA-approved drug for erectile dysfunction. The federal agency said tadalafil can interact with nitrates found in some prescription drugs, lowering blood pressure to dangerous levels....

2009-04-15 07:00:00

A Drug With Greater Efficacy than Levitra for Patients with Hypertension Priced at a Five Percent Discount to Levitra Would Earn a 50 Percent Patient Share in the U.S., According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although surveyed primary care physicians (PCPs) are generally satisfied with the efficacy of available...

c2bccecf46832532548cfe04b0ed1b011
2009-04-14 15:43:34

A new study has shown treatments for erectile dysfunction, such as the hugely popular drug Viagra, do not appear to pose long-term damage to men's sight. Doctors were concerned that Viagra and other drugs like it might be harmful after some men reported blurred and blue-tinged vision. Viagra and Cialis, another big erectile dysfunction drug, account for a billion dollars in sales in 2008. According to the results published in the April issue of Archives of Ophthalmology, the six-month study...

2009-04-14 07:59:02

Two medications used to treat erectile dysfunction in men (tadalafil and sildenafil) do not appear to have visual side effects when taken daily for six months, despite concerns about eye-related complications, according to a report in the April issue of Archives of Ophthalmology, one of the JAMA/Archives journals.The advent of the medications sildenafil citrate (sold as Viagra), tadalafil (sold as Cialis) and verdenafil hydrochloride (sold as Levitra) has profoundly changed the treatment of...

2009-03-25 10:00:00

NEW YORK, March 25 /PRNewswire/ -- An amazing medical discovery that provides a permanent solution for Erectile Dysfunction (ED) is in the US and looking to make the big three ED pills obsolete. To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/bathmateus/37601/ Developed by engineers, originally marketed for male enhancement and now sold in the US at www.bathmateus.com, the Bathmate Hydropump reverses Erectile Dysfunction through its revolutionary use of water....


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'